Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Forum Dermatologicum
MENU
Shortcuts Submit an article Author Guidelines Ahead Of Print Reviewers 2023

Vol 8, No 2 (2022)
Review paper
Published online: 2022-03-24
Add to basket: 49.00 PLN
Get Citation

Sweet’s syndrome — etiopathogenesis, clinical presentation, diagnosis, treatment

Anna Czaplicka1, Jakub Biliński1, Klaudia Dopytalska1, Irena Walecka1
DOI: 10.5603/FD.a2022.0002
·
Forum Dermatologicum 2022;8(2):63-68.
Affiliations
  1. Klinika Dermatologii Centrum Medyczne Kształcenia Podyplomowego, Centralny Szpital Kliniczny MSWiA w Warszawie

paid access

Vol 8, No 2 (2022)
REVIEW ARTICLES
Published online: 2022-03-24

Abstract

Sweet’s syndrome is a rare inflammatory disorder belonging to the group of neutrophilic dermatoses. It is characterized by a sudden onset of skin lesions such as papules, nodules, plaques, accompanied by fever and leukocytosis. The syndrome is typically classified into the following subtypes: classical, malignancy-associated and drug-induced. The etiopathogenesis of Sweet’s syndrome remains unclear. The syndrome is sometimes preceded by infection of the respiratory system, digestive system, vaccination or coexists with neoplastic disease, inflammatory disease or pregnancy. A characteristic feature of Sweet’s syndrome is a good response to systemic treatment with glucocorticosteroids and a rapid resolution of the lesions. On average, one third of patients have recurrent lesions.

Abstract

Sweet’s syndrome is a rare inflammatory disorder belonging to the group of neutrophilic dermatoses. It is characterized by a sudden onset of skin lesions such as papules, nodules, plaques, accompanied by fever and leukocytosis. The syndrome is typically classified into the following subtypes: classical, malignancy-associated and drug-induced. The etiopathogenesis of Sweet’s syndrome remains unclear. The syndrome is sometimes preceded by infection of the respiratory system, digestive system, vaccination or coexists with neoplastic disease, inflammatory disease or pregnancy. A characteristic feature of Sweet’s syndrome is a good response to systemic treatment with glucocorticosteroids and a rapid resolution of the lesions. On average, one third of patients have recurrent lesions.

Full Text:

Add to basket: 49.00 PLN
Get Citation

Keywords

acute febrile neutrophilic dermatosis, neutrophilic dermatoses, Sweet’s syndrome

About this article
Title

Sweet’s syndrome — etiopathogenesis, clinical presentation, diagnosis, treatment

Journal

Forum Dermatologicum

Issue

Vol 8, No 2 (2022)

Article type

Review paper

Pages

63-68

Published online

2022-03-24

Page views

2412

Article views/downloads

42

DOI

10.5603/FD.a2022.0002

Bibliographic record

Forum Dermatologicum 2022;8(2):63-68.

Keywords

acute febrile neutrophilic dermatosis
neutrophilic dermatoses
Sweet’s syndrome

Authors

Anna Czaplicka
Jakub Biliński
Klaudia Dopytalska
Irena Walecka

References (15)
  1. Sweet RD. An acute febrile neutrophilic dermatosis. Br J Dermatol. 1964; 76: 349–356.
  2. Villarreal-Villarreal CD, Ocampo-Candiani J, Villarreal-Martínez A. Sweet Syndrome: A Review and Update. Actas Dermosifiliogr. 2016; 107(5): 369–378.
    CrossRefPubMed
  3. Nelson CA, Stephen S, Ashchyan HJ, et al. Neutrophilic dermatoses: Pathogenesis, Sweet syndrome, neutrophilic eccrine hidradenitis, and Behçet disease. J Am Acad Dermatol. 2018; 79(6): 987–1006.
    CrossRefPubMed
  4. Heath MS, Ortega-Loayza AG. Insights Into the Pathogenesis of Sweet's Syndrome. Front Immunol. 2019; 10: 414.
    CrossRefPubMed
  5. Marzano AV, Ortega-Loayza AG, Heath M, et al. Mechanisms of Inflammation in Neutrophil-Mediated Skin Diseases. Front Immunol. 2019; 10: 1059.
    CrossRefPubMed
  6. Nelson CA, Noe MH, McMahon CM, et al. Sweet syndrome in patients with and without malignancy: A retrospective analysis of 83 patients from a tertiary academic referral center. J Am Acad Dermatol. 2018; 78(2): 303–309.e4.
    CrossRefPubMed
  7. Kumar G, Bernstein JM, Waibel JS, et al. Sweet's syndrome associated with sargramostim (granulocyte-macrophage colony stimulating factor) treatment. Am J Hematol. 2004; 76(3): 283–285.
    CrossRefPubMed
  8. Nelis S, Azerad MA, Drowart A, et al. [Sweet's syndrome induced by pegfilgrastim during a myelodysplastic syndrome AREB2: A case report]. Rev Med Interne. 2019; 40(4): 258–261.
    CrossRefPubMed
  9. Pérez-Feal P, Pita da Veiga G, Moreiras-Arias N, et al. Sweet's syndrome triggered by ultraviolet light. Photodiagnosis Photodyn Ther. 2021; 34: 102258.
    CrossRefPubMed
  10. Ramsey AL, Wallace WD, Abtin F, et al. Sweet's Syndrome: A First in Human Lung Transplantation. Chest. 2021; 160(2): e173–e176.
    CrossRefPubMed
  11. Sechi A, Pierobon E, Pezzolo E, et al. Abrupt onset of Sweet syndrome, pityriasis rubra pilaris, pityriasis lichenoides et varioliformis acuta and erythema multiforme: unravelling a possible common trigger, the COVID-19 vaccine. Clin Exp Dermatol. 2022; 47(2): 437–440.
    CrossRefPubMed
  12. Darrigade AS, Théophile H, Sanchez-Pena P, et al. Sweet syndrome induced by SARS-CoV-2 Pfizer-BioNTech mRNA vaccine. Allergy. 2021; 76(10): 3194–3196.
    CrossRefPubMed
  13. von den Driesch P, von den Driesch P, Dannecker GE, et al. Sweet's syndrome (acute febrile neutrophilic dermatosis). J Am Acad Dermatol. 1994; 31: 535–556.
  14. Walker DC, Cohen PR. Trimethoprim-sulfamethoxazole-associated acute febrile neutrophilic dermatosis: case report and review of drug-induced Sweet's syndrome. J Am Acad Dermatol. 1996; 34(5 Pt 2): 918–923.
    CrossRefPubMed
  15. Shahid Z, Kalayanamitra R, Patel R, et al. Refractory Sweet Syndrome Treated with Anakinra. Cureus. 2019; 11(4): e4536.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
phone: +48 58 320 94 94, fax: +48 58 320 94 60, e-mail: viamedica@viamedica.pl